Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Denver, Colorado

This page shows live ClinicalTrials.gov search results for Denver, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7457
Shown on this page
12
Current sort
Recently updated
Location scope
Denver, CO
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Denver, Colorado. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 541–552 of 7,457 matching trials in Denver, CO.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Terminated No phase listed Observational Accepts healthy volunteers

VIA Disc NP Registry

NCT04652687
Conditions
Discogenic Pain, Back Pain, Back Pain, Low
Interventions
VIA Disc NP (HCT/P)
Other
Lead sponsor
VIVEX Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
32
States / cities
Mesa, Arizona • Santa Monica, California • Walnut Creek, California + 27 more
Conditions
Urinary Incontinence, Urinary Incontinence,Stress
Interventions
Adjustable Continence Therapy for Women (ACT)
Device
Lead sponsor
Uromedica
Industry
Eligibility
22 Years and older · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
5
States / cities
Denver, Colorado • Meridian, Idaho • Independence, Missouri + 2 more
Conditions
Advanced Solid Tumor, Malignant Solid Tumor
Interventions
Ifinatamab deruxtecan (I-DXd)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
10
States / cities
Denver, Colorado • Sarasota, Florida • Boston, Massachusetts + 6 more
Active, not recruiting Not applicable Interventional Results available

Reproductive Health Program in Patients With Cancer

NCT01806129
Conditions
Malignant Neoplasm
Interventions
Standard practice related to reproductive heath, Training modules, algorithm, referral development
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
15 Years to 55 Years · Female only
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
109
States / cities
Jonesboro, Arkansas • Aurora, Colorado • Boulder, Colorado + 80 more
Conditions
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure, Docetaxel, Goserelin Acetate, Laboratory Biomarker Analysis, Pertuzumab, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, Whole Breast Irradiation
Drug · Other · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
731
States / cities
Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
48
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more
Conditions
Soft Tissue Sarcoma
Interventions
Palifosfamide-Tris, doxorubicin, Placebo
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Conditions
Early Alzheimer's Disease
Interventions
Lecanemab IV, Placebo, Lecanemab SC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
112
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 82 more
Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 4 more
Conditions
Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
412
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more
Conditions
Breast Neoplasm, Neoplasm Metastasis
Interventions
Abemaciclib, Fulvestrant, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
60
States / cities
Phoenix, Arizona • Springdale, Arkansas • Fullerton, California + 52 more
Conditions
cGVHD
Interventions
Non-Interventional
Other
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more